Company intelligence / Profile preview

RNL

Seoul, Seoul, South Korea

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Nature Cell, formerly known as RNL Bio, is a South Korean biotechnology company specializing in the development of adult stem cell therapies. The company focuses on autologous adipose-derived mesenchymal stem cells (AD-MSCs) for treating degenerative diseases and autoimmune conditions. Its lead candidate, JointStem, is a treatment for knee osteoarthritis that has completed Phase 3 clinical trials in South Korea. The company also develops AstroStem for Alzheimer's disease and various cosmetic products based on stem cell technology. Despite past regulatory and legal challenges, it remains a significant player in the regenerative medicine sector in Asia.

Therapeutic areas: NeurologyImmunologyRheumatologyCardiovascular
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Partnerships

Biostar Stem Cell Research InstituteR-Japan

Beyond the preview

Go deeper on RNL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNL.

Explore the full profile